Kurz vor unserem ersten Jubiläum erreicht fair equity einen bedeutenden Meilenstein: Wir haben unsere erste sechsstellige Impact-Investition erfolgreich abgeschlossen und 250.000 € in Medpharma in Ghana investiert. Damit unterstützen wir ein Unternehmen, das einen entscheidenden Beitrag zur Verbesserung der Gesundheitsversorgung in Westafrika leistet.
Why we are investing in Medpharma
In Ghana – as in many African countries – access to medical care is severely limited. In some regions, a single doctor is responsible for up to 13,000 people. Millions of people lack reliable access to diagnosis, treatment, or medication.
Medpharma addresses exactly this challenge. The company is developing a digital 360° healthcare ecosystem that connects patients, medical professionals, pharmacies, and insurers. Through an app, a web platform, and an AI-powered chatbot, Medpharma enables:
-
digital medical consultations
-
AI diagnostics
-
home delivery of medications
-
access to health and life insurance
With this approach, Medpharma is creating access to healthcare where it has previously been scarce – efficiently, at scale, and accessible to broad segments of the population.
A founder with a clear vision
We are proud to support Stephen Yaw Asamoah, the founder of Medpharma. His commitment to digital, equitable, and affordable healthcare, combined with his strong execution, has fully convinced us.
A collaborative closing
The pre-seed funding round was successfully completed in partnership with Sahara Impact Ventures. For legal support, we extend our thanks to n. dowuona & company, whose expertise greatly facilitated the process.
Thanks to the fair equity team
Our thanks also go to our entire team – Karsten Wulf, Lutz Hethey, Gunnar Sander, Bernhard Mutsaers, Bernd Schmidt-Ankum, Klaus Stein, and Caroline Flohr – and especially to Vanessa Ennen, who has coordinated our investments with great care in her free time.
With this investment, we are sending a strong signal in support of impact-driven companies in developing and emerging markets, and we look forward to accompanying Medpharma on its continued growth journey.
